Washington-Watch
FDA General
More in FDA General
Despite problematic dataset, risk/benefit profile not favorable with PD-L1 expression below 1
Sep 27, 2024
Phase III trial program showed 30% to 34% reduction in moderate or severe exacerbations
Sep 27, 2024
EGFR inhibitor now indicated for unresectable stage III disease following chemoradiotherapy
Sep 25, 2024
Data since approvals suggest benefits limited to subgroups with PD-L1 expression of at least 1%
Sep 24, 2024
Broad indication doubles the number of patients eligible for adjuvant CDK4/6 inhibition
Sep 17, 2024